These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18972838)

  • 1. No association between Fas A/G polymorphism and therapeutic effects induced by methimazole treatment for Graves' disease in Northern Chinese.
    Li P; Li Q; Chen L; Sun Y; Zhang J
    Pharmazie; 2008 Oct; 63(10):748-50. PubMed ID: 18972838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between a C/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves' hyperthyroidism after antithyroid withdrawal in Taiwanese.
    Hsiao JY; Hsieh MC; Tien KJ; Hsu SC; Shin SJ; Lin SR
    J Clin Endocrinol Metab; 2007 Aug; 92(8):3197-201. PubMed ID: 17550957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
    Wu G; Jie Y; Situ Y
    Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
    Leite AC; Pedro AB; Romaldini JH
    Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spiking expression of mu-crystallin mRNA during treatment with methimazole in patients with graves' hyperthyroidism.
    Suzuki S; Takei M; Nishio S; Inaba H; Sato A; Yamazaki M; Shinomiya K; Hashizume K
    Horm Metab Res; 2009 Jul; 41(7):548-53. PubMed ID: 19280551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
    Liu C; Duan Y; Wu X
    Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polymorphism in FAS gene promoter correlated with circulating soluble FAS levels.
    Mahfoudh W; Bel Hadj Jrad B; Romdhane A; Chouchane L
    Int J Immunogenet; 2007 Jun; 34(3):209-12. PubMed ID: 17504511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Graves' disease in Brazilian children and adults: lack of genetic association with CTLA-4 +49A>G polymorphism.
    Namo Cury A; Longui CA; Kochi C; Calliari LE; Scalissi N; Salles JE; Neves Rocha M; Barbosa de Melo M; Rezende Melo M; Monte O
    Horm Res; 2008; 70(1):36-41. PubMed ID: 18493148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
    Nielsen CH; El Fassi D; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves' disease.
    Kim KW; Park YJ; Kim TY; Park DJ; Park KS; Cho BY
    Thyroid; 2007 Dec; 17(12):1229-34. PubMed ID: 17949264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between FAS polymorphism and prostate cancer development.
    Lima L; Morais A; Lobo F; Calais-da-Silva FM; Calais-da-Silva FE; Medeiros R
    Prostate Cancer Prostatic Dis; 2008; 11(1):94-8. PubMed ID: 17667965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.